Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Coherus BioSciencesInhibrxAdverum BiotechnologiesMesoblastCortexyme
SymbolNASDAQ:CHRSNASDAQ:INBXNASDAQ:ADVMNASDAQ:MESONASDAQ:CRTX
Price Information
Current Price$14.39$18.03$8.86$8.94$38.70
52 Week RangeBuyBuyBuyHoldHold
MarketRank™
Overall Score1.41.61.51.41.3
Analysis Score3.43.53.43.23.1
Community Score2.52.92.43.12.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.00.8
Earnings & Valuation Score1.30.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldHold
Consensus Price Target$26.60$34.67$23.50$14.55$50.00
% Upside from Price Target84.85% upside92.27% upside165.24% upside62.75% upside29.20% upside
Trade Information
Market Cap$1.05 billion$680.60 million$866.47 million$1.16 billion$1.14 billion
Beta1.57N/A1.723.710.95
Average Volume1,329,158146,904837,737582,213305,699
Sales & Book Value
Annual Revenue$356.07 millionN/A$250,000.00$32.16 millionN/A
Price / Sales2.95N/A3,465.8936.07N/A
Cashflow$1.08 per shareN/AN/AN/AN/A
Price / Cash13.36N/AN/AN/AN/A
Book Value$1.50 per shareN/A$2.71 per share$4.70 per share$4.30 per share
Price / Book9.59N/A3.271.90N/A
Profitability
Net Income$89.83 millionN/A$-64,490,000.00$-77,940,000.00$-36,980,000.00
EPS$1.23N/A($1.01)($0.74)($1.94)
Trailing P/E Ratio7.050.00N/AN/AN/A
Forward P/E Ratio16.35N/AN/AN/AN/A
P/E Growth9.34N/AN/AN/AN/A
Net Margins33.06%N/AN/A-591.00%N/A
Return on Equity (ROE)90.98%N/A-32.23%-18.69%-37.78%
Return on Assets (ROA)27.33%N/A-28.02%-13.85%-35.24%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.58%0.18%N/A0.10%N/A
Current Ratio5.45%3.80%28.53%1.32%8.71%
Quick Ratio5.18%3.80%28.53%1.32%8.71%
Ownership Information
Institutional Ownership PercentageN/A36.63%97.41%2.80%55.48%
Insider Ownership Percentage15.86%N/A12.40%18.80%19.80%
Miscellaneous
Employees3178416710237
Shares Outstanding73.11 million37.75 million97.80 million129.74 million29.55 million
Next Earnings Date5/6/2021 (Estimated)6/11/2021 (Estimated)5/27/2021 (Estimated)5/26/2021 (Estimated)5/11/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Cortexyme Inc (CRTX) is down -0.97% in a Week, Should You Sell? - InvestorsObserverCortexyme Inc (CRTX) is down -0.97% in a Week, Should You Sell? - InvestorsObserver
investorsobserver.com - April 13 at 3:10 PM
Cortexyme (NASDAQ:CRTX) Stock Price Up 7%Cortexyme (NASDAQ:CRTX) Stock Price Up 7%
americanbankingnews.com - April 13 at 2:02 PM
Where Will Cortexyme Inc (CRTX) Stock Go Next After It Is Lower By 6.77% in a Week? - InvestorsObserverWhere Will Cortexyme Inc (CRTX) Stock Go Next After It Is Lower By 6.77% in a Week? - InvestorsObserver
investorsobserver.com - April 9 at 8:01 PM
Cortexyme (NASDAQ:CRTX) Shares Gap Down to $35.90Cortexyme (NASDAQ:CRTX) Shares Gap Down to $35.90
americanbankingnews.com - April 9 at 11:42 AM
Is Cortexyme Inc (CRTX) a Stock to Watch After Losing -3.90% This Week? - InvestorsObserverIs Cortexyme Inc (CRTX) a Stock to Watch After Losing -3.90% This Week? - InvestorsObserver
investorsobserver.com - March 31 at 3:32 PM
Cortexyme (NASDAQ:CRTX) Shares Gap Down to $32.51Cortexyme (NASDAQ:CRTX) Shares Gap Down to $32.51
americanbankingnews.com - March 30 at 1:04 PM
Cortexyme Inc (CRTX) Stock Is Up 0.71% This Week: Buy, Hold, or Sell? - InvestorsObserverCortexyme Inc (CRTX) Stock Is Up 0.71% This Week: Buy, Hold, or Sell? - InvestorsObserver
investorsobserver.com - March 26 at 3:02 PM
Thursday 3/25 Insider Buying Report: CRTXThursday 3/25 Insider Buying Report: CRTX
marketwatch.com - March 26 at 4:48 AM
Cortexyme, Inc. (NASDAQ:CRTX) Receives Consensus Rating of "Hold" from BrokeragesCortexyme, Inc. (NASDAQ:CRTX) Receives Consensus Rating of "Hold" from Brokerages
americanbankingnews.com - March 26 at 2:40 AM
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Yahoo FinanceCortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Yahoo Finance
finance.yahoo.com - March 25 at 11:23 PM
Hedge Fund and Insider Trading News: Ray Dalio, Greg Coffey, Whitebox Advisors, Glenview Capital Management, Effissimo Capital Management, Cortexyme Inc (CRTX), Skillz Inc (SKLZ), and MoreHedge Fund and Insider Trading News: Ray Dalio, Greg Coffey, Whitebox Advisors, Glenview Capital Management, Effissimo Capital Management, Cortexyme Inc (CRTX), Skillz Inc (SKLZ), and More
feedproxy.google.com - March 25 at 1:44 PM
Thursday 3/25 Insider Buying Report: CRTX - NasdaqThursday 3/25 Insider Buying Report: CRTX - Nasdaq
nasdaq.com - March 25 at 1:21 PM
Cortexyme Inc (CRTX) Stock:Do Analysts Think You Should Accumulate? - InvestorsObserverCortexyme Inc (CRTX) Stock:Do Analysts Think You Should Accumulate? - InvestorsObserver
investorsobserver.com - March 25 at 1:21 PM
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Argus PressCortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Argus Press
argus-press.com - March 25 at 1:21 PM
Cortexyme (NASDAQ:CRTX) Stock Price Up 2.9% Following Insider Buying ActivityCortexyme (NASDAQ:CRTX) Stock Price Up 2.9% Following Insider Buying Activity
americanbankingnews.com - March 25 at 10:32 AM
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Chronicle-TribuneCortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 - Chronicle-Tribune
chronicle-tribune.com - March 25 at 8:20 AM
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021
finance.yahoo.com - March 25 at 8:20 AM
Cortexyme Inc (CRTX) CEO Casey Lynch Sold $1.1 million of SharesCortexyme Inc (CRTX) CEO Casey Lynch Sold $1.1 million of Shares
gurufocus.com - March 23 at 10:59 PM
Facebook page of Georgia sheriffs spokesman appeared to promote racist shirt - Yahoo! VoicesFacebook page of Georgia sheriff's spokesman appeared to promote racist shirt - Yahoo! Voices
yahoo.com - March 19 at 9:51 AM
Cortexyme (CRTX) Investor Presentation - SlideshowCortexyme (CRTX) Investor Presentation - Slideshow
seekingalpha.com - March 17 at 1:28 PM
Why Express Stock Rocketed by 40% at the Open Today - NasdaqWhy Express Stock Rocketed by 40% at the Open Today - Nasdaq
nasdaq.com - March 11 at 8:56 AM
Independent Director David Lamond Just Bought 2.4% More Shares In Cortexyme, Inc. (NASDAQ:CRTX) - NasdaqIndependent Director David Lamond Just Bought 2.4% More Shares In Cortexyme, Inc. (NASDAQ:CRTX) - Nasdaq
nasdaq.com - March 10 at 2:32 PM
Dada Nexus Limited (NASDAQ:DADA) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? - NasdaqDada Nexus Limited (NASDAQ:DADA) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? - Nasdaq
nasdaq.com - March 10 at 9:32 AM
Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 - Business WireCortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 - Business Wire
businesswire.com - March 10 at 9:32 AM
Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021
finance.yahoo.com - March 10 at 9:32 AM
DateCompanyBrokerageAction
3/3/2021Coherus BioSciencesHC WainwrightLower Price Target
2/25/2021Coherus BioSciencesCitigroupLower Price Target
11/19/2020Coherus BioSciencesMizuhoLower Price Target
8/7/2020Coherus BioSciencesMaxim GroupInitiated Coverage
7/16/2020Coherus BioSciencesBank of AmericaInitiated Coverage
4/17/2020Coherus BioSciencesSunTrust BanksInitiated Coverage
3/5/2020Coherus BioSciencesCredit Suisse GroupReiterated Rating
2/6/2020Coherus BioSciencesJPMorgan Chase & Co.Boost Price Target
8/12/2019Coherus BioSciencesBarclaysSet Price Target
10/15/2020InhibrxLifesci CapitalReiterated Rating
9/14/2020InhibrxJefferies Financial GroupInitiated Coverage
9/14/2020InhibrxEvercore ISIInitiated Coverage
3/2/2021Adverum BiotechnologiesCantor FitzgeraldReiterated Rating
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
8/11/2020Adverum BiotechnologiesSVB LeerinkBoost Price Target
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
6/16/2020Adverum BiotechnologiesRoyal Bank of CanadaBoost Price Target
5/30/2020Adverum BiotechnologiesChardan CapitalReiterated Rating
4/28/2020Adverum BiotechnologiesThe Goldman Sachs GroupInitiated Coverage
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
9/10/2019MesoblastOppenheimerSet Price Target
12/11/2020CortexymeSmith Barney CitigroupInitiated Coverage
12/11/2020CortexymeCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
5/13/2020CortexymeCanaccord GenuityReiterated Rating
6/3/2019CortexymeJMP SecuritiesInitiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.